Pzena Investment Management LLC cut its stake in USANA Health Sciences, Inc. (NYSE:USNA – Free Report) by 6.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,134,429 shares of the company’s stock after selling 78,159 shares during the quarter. Pzena Investment Management LLC owned 6.21% of USANA Health Sciences worth $22,269,000 at the end of the most recent quarter.
Other institutional investors and hedge funds also recently modified their holdings of the company. National Bank of Canada FI increased its stake in shares of USANA Health Sciences by 166.6% in the 3rd quarter. National Bank of Canada FI now owns 1,922 shares of the company’s stock valued at $53,000 after acquiring an additional 1,201 shares during the last quarter. Tower Research Capital LLC TRC increased its stake in shares of USANA Health Sciences by 382.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,398 shares of the company’s stock valued at $73,000 after acquiring an additional 1,901 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of USANA Health Sciences by 52.9% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,834 shares of the company’s stock valued at $106,000 after acquiring an additional 1,327 shares during the last quarter. Quantbot Technologies LP increased its stake in shares of USANA Health Sciences by 19.5% in the 2nd quarter. Quantbot Technologies LP now owns 3,957 shares of the company’s stock valued at $121,000 after acquiring an additional 646 shares during the last quarter. Finally, iSAM Funds UK Ltd bought a new stake in shares of USANA Health Sciences in the 3rd quarter valued at about $120,000. 54.25% of the stock is owned by institutional investors.
USANA Health Sciences Stock Up 2.9%
Shares of USANA Health Sciences stock opened at $18.66 on Friday. USANA Health Sciences, Inc. has a 12-month low of $16.60 and a 12-month high of $38.32. The stock has a market cap of $344.46 million, a P/E ratio of 39.70, a P/E/G ratio of 0.71 and a beta of 0.77. The business’s 50 day moving average is $18.16 and its 200-day moving average is $19.52.
Analyst Upgrades and Downgrades
USNA has been the subject of several research analyst reports. Weiss Ratings reiterated a “sell (d)” rating on shares of USANA Health Sciences in a research report on Friday, March 27th. Wall Street Zen lowered USANA Health Sciences from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. Finally, Zacks Research lowered USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 22nd. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Reduce”.
View Our Latest Report on USNA
Insider Activity
In other news, insider Joshua Foukas sold 3,791 shares of the company’s stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $19.82, for a total transaction of $75,137.62. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 0.82% of the stock is currently owned by corporate insiders.
About USANA Health Sciences
USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.
Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.
Read More
- Five stocks we like better than USANA Health Sciences
- Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending
- As Small-Cap Outperformance Continues, These 2 ETFs Provide Exposure
- Silicon Shake-Up: The AI Trade Is Moving Beyond NVIDIA
- The Silver Lining of Last Week’s Hims & Hers Earnings Miss
Want to see what other hedge funds are holding USNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for USANA Health Sciences, Inc. (NYSE:USNA – Free Report).
Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
